Videos

This video provides comprehensive review of current minimally invasive BPH therapies, focusing on safety, patient experience, and key distinctions between procedural categories.

Jennifer U. Miles-Thomas, MD, MBA, reflects on the key pillars to building successful surgeon/advanced practice providers partnerships.

In the FIT-001 trial, the combination of darlifarnib and cabozantinib demonstrated promising early antitumor activity in patients with ccRCC who had previously progressed on cabozantinib.

This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.

This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.

Song Jiang, MD, discusses evolving biomarker approaches that may redefine care in NMIBC.

Song Jiang, MD, PhD, discusses the balance between efficacy and safety data when considering the role for BCG/ICI combinations in BCG-naive NMIBC.

Charles R. Powell, MD, discusses how the rise of GLP-1–associated weight loss may influence outcomes and device management in sacral neuromodulation.

In this segment, Dr. Charles J. Ryan presents a clinical case scenario to explore how real world evidence informs treatment decisions in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan and the panel explore how clinicians interpret subgroup analyses, pivotal trial data, and real world evidence when managing metastatic castration sensitive prostate cancer (mCSPC).

Akanksha Mehta, MD, MS, discusses why the updated vasectomy guideline expands its focus on fertility restoration, emphasizing patient counseling on reversal and individualized decision-making for future family building.

Adanma Ayanambakkam, MD, MS, discusses the FIT-001 trial and early findings on the safety profile for darlifarnib plus cabozantinib in ccRCC.

Real-world PSMA PET in prostate cancer reveals reporting variability, limits at low PSA, and mixed FDG PET value—what clinicians learn in practice.

PSMA PET interpretation standards evolve, with SUV reporting and staging differences across settings shaping therapy choices, sequencing, and metastasis-directed radiation decisions.

Helen L. Bernie, DO, MPH, discusses how expanded TRT labeling could improve care for men with idiopathic hypogonadism.

Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.

Daniel J. George, MD, highlights survey findings on the role of caregivers in the treatment journey for patients with metastatic prostate cancer.

In this video, Dalia Kaakour, MD, MPH, highlights retrospective findings on the use of ctDNA in detecting residual disease and recurrence in testicular cancer.

In this video, Meri-Margaret Deoudes discusses ongoing challenges for patients with bladder cancer, including costs of care, delayed diagnoses among women, and access barriers among patients in rural areas.

PSMA PET scans reshape prostate cancer care—learn who should interpret results, how reports vary, and why a team approach guides treatment.

Learn how emerging advanced scans outpace CT and bone scans in finding micrometastatic prostate cancer and shaping treatment teamwork.

C. Shawn West, MD, provides an overview of the pre-MIST era in BPH management, highlighting the reliance on invasive surgical approaches and the clinical and patient-centered limitations that drove innovation.

Suction-enabled URS platforms and AI-driven prediction and planning tools represent 2 parallel frontiers in kidney stone management, with active fragment evacuation already in clinical use and artificial intelligence poised to reshape preoperative planning, patient selection, and intraoperative guidance.

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians interpret clinical trial results in the context of real world patient populations with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan leads a panel discussion with Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram on key clinical considerations that influence treatment selection when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC).

David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC.

Robert Flavell, MD, PhD, and Anil P. Bidkar, PhD, discuss the synergistic potential of CD46-directed alpha radiation and ADC therapy combination.

Akanksha Mehta, MD, MS, discusses AUA guideline recommendations for performing post-vasectomy semen analysis.

Neha Vapiwala, MD, FASTRO, discusses the integration of radiation therapy with systemic treatment intensification across different stages of localized and locally advanced prostate cancer.